ALK inhibitors and advanced non-small cell lung cancer (Review)

Rossi,Antonio; Maione,Paolo; Sacco,Paola  Claudia; Sgambato,Assunta; Casaluce,Francesca; Ferrara,Marianna  Luciana; Palazzolo,Giovanni; Ciardiello,Fortunato; Gridelli,Cesare

doi:10.3892/ijo.2014.2475

ALK inhibitors and advanced non-small cell lung cancer (Review)

Authors:
- Antonio Rossi
- Paolo Maione
- Paola Claudia Sacco
- Assunta Sgambato
- Francesca Casaluce
- Marianna Luciana Ferrara
- Giovanni Palazzolo
- Fortunato Ciardiello
- Cesare Gridelli
View Affiliations

Affiliations: Division of Medical Oncology, ‘S.G. Moscati’ Hospital, Avellino, Italy, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy, Division of Medical Oncology, ‘ULSS 15 Cittadella’, Padova, Italy
Published online on: May 29, 2014 https://doi.org/10.3892/ijo.2014.2475
Pages: 499-508

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. Histology and molecular analyses are the cornerstone in the initial diagnosis of NSCLC and are key determinants to address the appropriate strategy of treatment. In non-squamous histology the combination of cisplatin plus pemetrexed or carboplatin plus paclitaxel plus bevacizumab are considered today the best regimens yielding better activity and efficacy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. The identification of anaplastic lymphoma kinase (ALK) rearrangements in 2-5% of NSCLC patients led to the rapid clinical development of its oral TKI, crizotinib, also targeting the proto-oncogene MET and ROS1. The results reported from the first phase III trial showed superiority of crizotinib compared with standard chemotherapy in second-line treatment of ALK-positive NSCLC, which was recently approved in several countries in this setting. Unfortunately, after initial activity of crizotinib, patients will ultimately develop acquired resistances within 1 or 2 years of therapy. A second generation of ALK inhibitors, such as LDK378, alectinib and AP26113 may represent a promising treatment approach: they are under investigation with very promising early results. This review discusses ALK rearrangements, the clinical development and use of crizotinib, and other ALK-TKIs in advanced NSCLC.

View Figures

View References

1	Rossi A, Torri V, Garassino MC, Porcu L and Galetta D: The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treat Rev. 40:485–494. 2014. View Article : Google Scholar : PubMed/NCBI
2	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rossi A, Pasquale R, Esposito C and Normanno N: Should epidermal growth factor receptor tyrosine kinae inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev. 39:489–497. 2013. View Article : Google Scholar
5	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
6	Amin HM and Lai R: Pathobiology of ALK⁺ anaplastic large-cell lymphoma. Blood. 110:2259–2267. 2007.PubMed/NCBI
7	Chiarle R, Voena C, Ambrogio C, Piva R and Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 8:11–23. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sasaki T, Rodig SJ, Cirieac LR and Janne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI
9	Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
10	Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
11	Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
12	Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhang X, Zhang S, Yang X, et al: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
16	Koh Y, Kim DW, Kim TM, et al: Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma. J Thorac Oncol. 6:905–912. 2011. View Article : Google Scholar
17	Barlesi F, Blons H, Beau-Faller M, et al: Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 31:80002013.
18	Johnson BE, Kris MG, Berry LD, et al: A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 31:80192013.
19	Rosell R, Massuti Sureda B, Costa C, et al: Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK. Ann Oncol. 23(Suppl 9): ixe22 (LBA31)2012.
20	Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar
21	Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guidelinefor selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors; guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 8:823–859. 2013.
22	Camidge DR, Kono SA, Flacco A, et al: Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 16:5581–5590. 2010. View Article : Google Scholar
23	Park HS, Lee JK, Kim DW, et al: Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 77:288–292. 2012. View Article : Google Scholar : PubMed/NCBI
24	Minca EC, Portier BP, Wang Z, et al: ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 15:341–346. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sholl LM, Weremowicz S, Gray SW, et al: Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol. 8:322–328. 2013. View Article : Google Scholar : PubMed/NCBI
26	Martinez P, Hernández-Losa J, Montero MÁ, et al: Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One. 8:e522612013. View Article : Google Scholar : PubMed/NCBI
27	Conklin CM, Craddock KJ, Have C, et al: Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
28	Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007. View Article : Google Scholar : PubMed/NCBI
29	Cui JJ, Tran-Dubé M, Shen H, et al: Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 54:6342–6363. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kwak EL, Camidge DR, Clark J, et al: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol. 27(15S): 148s35092009.
31	Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
32	Camidge DR, Bang Y-B, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
33	Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
34	Kim D, Ahn M, Yang P, et al: Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Ann Oncol. 23(Suppl 9): ix4021230PD2012.
35	Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar
36	Weickhardt AJ, Rothman MS, Salian-Mehta S, et al: Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 118:5302–5309. 2012. View Article : Google Scholar : PubMed/NCBI
37	Weickhardt AJ, Doebele RC, Purcell WT, et al: Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 119:2383–2390. 2013. View Article : Google Scholar : PubMed/NCBI
38	A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung (PROFILE 1014). http://clinicaltrials.gov/ct2/show/NCT01154140. Accessed March 15, 2014
39	Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
40	Sasaki T, Koivunen J, Ogino A, et al: A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71:6051–6060. 2011. View Article : Google Scholar : PubMed/NCBI
41	Katayama R, Khan TM, Benes C, et al: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI
42	Zhang S, Wang F, Keats J, et al: Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 78:999–1005. 2011. View Article : Google Scholar : PubMed/NCBI
43	Katayama R, Shaw AT, Khan TM, et al: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 4:120ra172012.PubMed/NCBI
44	Doebele RC, Pilling AB, Aisner DL, et al: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 18:1472–1482. 2012. View Article : Google Scholar : PubMed/NCBI
45	Lovly CM and Pao W: Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med. 4:120ps22012.PubMed/NCBI
46	Doebele RC, Aisner DL, Le AT, et al: Analysis of resistance mechanisms to ALK kinase inhibitors in ALK⁺ NSCLC patients. J Clin Oncol. 30(15S): 75042012.
47	Camidge DR, Bang Y, Kwak EL, et al: Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 29(15S): 25012011.
48	Shaw AT, Mehra R, Kim DW, et al: Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol. 31(15S): 80102013.
49	Shaw AT, Mok T, Spigel DR, et al: A phase II single-arm study of LDK378 in patients with ALK-activated (ALK⁺) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 31(15S): TPS81192013.
50	Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013.PubMed/NCBI
51	Gadgeel S, Ou SH, Chiappori AA, et al: A Phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ non-small cell lung cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028). J Thorac Oncol. 8(Suppl 2): S199, O16.062013.
52	A study of RO5424802 in patients with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment. http://clinicaltrials.gov/show/NCT01801111. Accessed March 15, 2014
53	Camidge DR, Bazhenova L, Salgia R, et al: First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol. 31(15S): 80312013.
54	Chen Z, Sasaki T, Tan X, et al: Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70:9827–9836. 2010. View Article : Google Scholar : PubMed/NCBI
55	Socinski MA, Goldman J, El-Hariry I, et al: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013. View Article : Google Scholar : PubMed/NCBI
56	Sequist LV, Gettinger S, Senzer NN, et al: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI
57	Felip E, Carcereny E, Barlesi F, et al: Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK-rearranged (ALK⁺) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 23(Suppl 9): ix152–ix174. 4382012.
58	A study of ganetespib in subjects with ALK-positive non-small-cell lung cancer (NSCLC) (CHIARA). http://clinicaltrials.gov/show/NCT01562015. Accessed March 15, 2014
59	Crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. http://clinicaltrials.gov/show/NCT01579994. Accessed March 15, 2014
60	AUY922 for advanced ALK-positive NSCLC. http://clinicaltrials.gov/show/NCT01752400. Accessed March 15, 2014
61	Phase Ib study of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer. http://clinicaltrials.gov/show/NCT01772797. Accessed March 15, 2014
62	Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 6:774–780. 2011. View Article : Google Scholar : PubMed/NCBI
63	Lee JO, Kim TM, Lee SH, et al: Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 6:1474–1480. 2011. View Article : Google Scholar : PubMed/NCBI
64	Takezawa K, Okamoto I, Okamoto W, et al: Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 104:1594–1601. 2011. View Article : Google Scholar : PubMed/NCBI
65	Shaw AT, Varghese AM, Solomon BJ, et al: Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 24:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
66	Rimkunas VM, Crosby KE, Li D, et al: Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 18:4449–4457. 2012. View Article : Google Scholar
67	Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012. View Article : Google Scholar : PubMed/NCBI
68	Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
69	Yasuda H, de Fiqueiredo-Pontes LL, Kobayashi S and Costa DB: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 7:1086–1090. 2012. View Article : Google Scholar
70	Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 30(15S): 75082012.
71	Awad MM, Katayama R, McTigue M, et al: Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 368:2395–2401. 2013. View Article : Google Scholar : PubMed/NCBI
72	Weickhardt AJ, Scheier B, Burke JM, et al: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer. J Thorac Oncol. 7:1807–1814. 2012. View Article : Google Scholar : PubMed/NCBI
73	Costa DB, Kobayashi S, Pandya SS and Yeo WL: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 29:e443–e445. 2012. View Article : Google Scholar : PubMed/NCBI
74	Chun SG, Choe KS, Iyengar P, Yordy JS and Timmerman RD: Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocations? Cancer Biol Ther. 13:1376–1383. 2012. View Article : Google Scholar : PubMed/NCBI
75	Maillet D, Martel-Lafay I, Arpin D and Perol M: Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol. 8:e30–e31. 2013. View Article : Google Scholar : PubMed/NCBI
76	Kim YH, Ozasa H, Nagai H, et al: High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol. 8:e85–e86. 2013. View Article : Google Scholar : PubMed/NCBI
77	Kinoshita Y, Koga Y, Sakamoto A and Hidaka K: Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Rep. 2013. View Article : Google Scholar
78	Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr and Hirsch FR: Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 8:e112–e113. 2013. View Article : Google Scholar : PubMed/NCBI
79	Ou SH, Gadgeel S, Chiappori AA, et al: Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028). J Thorac Oncol. 8(Suppl 2): S200 O16.07. 2013.
80	Loscher W and Potschka H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2:86–98. 2005. View Article : Google Scholar : PubMed/NCBI